MYNZ
Mainz Biomed B.V.NASDAQHealthcare$0.70-5.07%ClosedMarket Cap: $2.9M
As of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.07
P/S
6.41
EV/EBITDA
-0.14
DCF Value
$-1.68
FCF Yield
-302.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.3%
Operating Margin
-2091.2%
Net Margin
-2421.8%
ROE
-465.8%
ROA
-211.8%
ROIC
-192.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $250.4K | $-7.9M | $-0.05 |
| FY 2025 | $537.1K | $-16.2M | $-2.70 |
| Q2 2025 | $286.7K | $-8.3M | $-2.65 |
| Q4 2024 | $373.2K | $-10.6M | $-7.71 |
Trading Activity
Insider Trades
View AllLazar David E.director
SellTue Mar 03
Lazar David E.director
SellTue Mar 03
Caragol William Jofficer: Chief Financial Officer
SellThu Feb 19
Dreismann Heinrichdirector
SellThu Feb 19
Tibbitts Gregory Jdirector
SellThu Feb 19
Company Info
Sector
Healthcare
Industry
—
Country
DE
Exchange
NASDAQ
Beta
0.32
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.